Literature DB >> 6228583

In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo.

G Forni, M Giovarelli.   

Abstract

Spleen cells from BALB/c mice bearing a small, but already clinically evident transplantable methylcholanthrene-induced sarcoma (CE-2) are not able to release interferons, proliferate and perform a cytotoxic response against CE-2 cells, nor able to inhibit their growth in vivo in a Winn-type neutralization assay. They can, however, be reeducated to be efficiently active against the tumor. Spleen cells (25 X 10(6) ) and 10(6) mitomycin C-treated CE-2 cells were cultured in 20 ml of medium for 6 days. The surviving spleen cells were then cultured for another 5 days under the same conditions plus 10% interleukin 2-rich supernatant from a clone of EL-4 thymoma cells stimulated with phorbol-12-myristate-13-acetate. Reeducated spleen cells were then able to inhibit the growth of a 100% lethal dose of CE-2 tumor cells in a Winn-type assay, even when the lymphocyte to tumor cell ratio was 5:1. In vitro, they released interferon-gamma when restimulated by CE-2 cells, and displayed a marked cytotoxicity in an 18-hr assay. Their in vivo tumor-neutralizing activity was not affected by the removal of Lyt-2.2+ lymphocytes, nor by the absorption of cytolytic cells on CE-2 monolayers. The absorbed cell population no longer contained cytotoxic cells nor cytotoxic cell precursors, but still contained CE-2-specific helper cells, which assist the in vitro induction of cytotoxic cells by normal thymocytes. Lyt-2.2-, noncytotoxic, reeducated spleen cells from tumor-bearing mice thus play an important role in tumor neutralization in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6228583

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Evaluation of in vivo and in vitro effectivity of immune defense against a spontaneously arising, nonlymphoid rat tumor. II. T cell response after induction of immunogenicity.

Authors:  M Zöller
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Correlation of tumor specific delayed type hypersensitivity reaction and tumor protection to SV40-induced mKSA fibrosarcoma.

Authors:  S Kadhim; J Barrington-Leigh
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

6.  Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma.

Authors:  L Grazioli; M Sensi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Inhibition of growth and metastasis of syngeneic transplantable tumours by an aromatic retinoic acid analogue. 2. T cell dependence of retinoid effects in vivo.

Authors:  S A Eccles; H P Purvies; S C Barnett; P Alexander
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

Review 8.  Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.

Authors:  G Forni; H Fujiwara; F Martino; T Hamaoka; C Jemma; P Caretto; M Giovarelli
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.